Top best answers to the question «New biological targets for drug development»
- In general, "new targets" are all those targets that are not "established targets" but which have been or are the subject of drug discovery efforts. The majority of targets selected for drug discovery efforts are proteins, such as G-protein-coupled receptors (GPCRs) and protein kinases.
8 other answers
A biological target, even one with validating data, will only be useful for drug development if it is possible to make molecules that affect the target in a way that could be well tolerated and therapeutically useful. Furthermore, those molecules must be shown to have properties enabling them to act like a medicine when given to people.
Potential new targets for drug development are being investigated, such as IL-13, IL-4α receptor, CRTH2, TSLP, IL-25, IL-13, IL-17A receptor, and CXCR2/IL-8. This review will discuss the role of these molecules on the inflammatory response in uncontrolled asthma and the emerging biologics that address them.
Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader' modules found in proteins with varied functions, were highly tractable small-molecule targets. This is an unusual property for protein-protein or protein-peptide interaction domains, and it prompted a wave of chemical probe discovery to understand the biological potential of new agents that targeted bromodomains.
As such, one of the most important steps in developing a new drug is target identification and validation. A target is a broad term which can be applied to a range of biological entities which may include for example proteins, genes and RNA.
Target identification in drug discovery Identifying the biological origin of a disease, and the potential targets for intervention, is the first step in the discovery of a medicine. More an art than a science, target identification is grounded in a number of different approaches and technologies, many of which are used in Roche research and early development.
New Treatment Targets. There is a real need to uncover new biology in order to advance more precision-based therapeutic strategies for patients with COPD. New disease-specific strategies in development are focusing on inflammatory pathways, hoping this will help to address disease onset.
In target-based drug discovery, biological (drug) targets are already established (or ‘discovered’) before lead discovery starts – hence target discovery is the cornerstone of target-based screening. 6 The target’s role in a disease process is known, this target is then used to create relevant systems-based assays, and vast compound libraries are screened in search of a ‘hit’ – a candidate drug. 3,4
21/8/11 4 • To bring a new drug to market requires a good understanding of drug development process & integral role preclinical testing plays in that process. • 5000– 10,000 compounds yield 1 new drug to market. • Overall time required for successful results is 10- 12 years. 5.